28 September 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Director/PDMR Shareholding
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class drugs in the high value and high growth oncology segment, advises that Stephen West, Executive Chairman and Dr Simon Sinclair, a Non-Executive Director have purchased ordinary shares in the Company in the market, as detailed below:
|
Name | Number of Ordinary Shares | Average Price Paid Per Share | Total Consideration Paid |
| Stephen West | 244,656 | 8.175 pence | £19,999.79 |
| Simon Sinclair | 60,415 | 8.276 pence | £4,999.97 |
Following the above purchase of shares, Stephen West and Simon Sinclair hold interests in the following Company securities:
|
Name | Number of Ordinary Shares Held | % of Issued Share Capital | Number of Warrants Held |
| Stephen West | 5,313,264 | 4.11% | 7,500,000 |
| Simon Sinclair | 60,415 | 0.05% | 300,000 |
4,628,485 of Mr West's shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.
Enquiries:
| ||||||||
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of four fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· MK cell therapy with direct and NK-mediated anti-cancer action; and
· siRNA targeting novel STAT-6 target in solid tumours showing significant in vivo efficacy.
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on Twitter.
This announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("UK MAR").
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Stephen West | |
| 2 | Reason for the notification | ||
| a) | Position/status | Executive Chairman | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value
ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Purchase of 244,656 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | 8.000 pence per share 8.215 pence per share 8.000 pence per share 8.250 pence per share | 62,040 60,416 62,040 60,160 | |
| d | Aggregated information - Aggregated volume - Price |
- 244,656 - 8.175p | |
| e) | Date of the transactions | 27 September 2022 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market | |
The notification below, made in accordance with the requirements of the UK MAR, provides further detail:
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||
| a) | Name | Dr Simon Sinclair | |
| 2 | Reason for the notification | ||
| a) | Position/status | Non-Executive Director | |
| b) | Initial notification /Amendment | Initial | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Roquefort Therapeutics plc | |
| b) | LEI | 254900P4SISIWOR9RH34 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 par value
ISIN: GB00BMDQ2T15 | |
| b) | Nature of the transaction | Purchase of 60,415 ordinary shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| | 8.276 pence per share | 60,415
| |
| d | Aggregated information - Aggregated volume - Price |
- 60,415 - 8.276p | |
| e) | Date of the transactions | 27 September 2022 | |
| f) | Place of the transactions | London Stock Exchange (XLON); Main Market | |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.